Stocks · News reference
Filed: 2026-08-27 AccNo: 0001193125-26-369674 Size: 235 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durableone-year clinical benefitGlobal registrational trial to enroll approximately 160 adults with HP to support
Read original at benzingaJP Morgan analyst Jessica Fye reinstates MBX Biosciences (NASDAQ:MBX) with a Overweight and announces $88 price target.
Read original at benzingaTruist Securities analyst Srikripa Devarakonda maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $70 to $88.
Read original at benzinga